Introduction: Patients with Diffused large B cell lymphoma (DLBCL) who are also co-infected with Hepatitis B virus (HBV) may experience HBV reactivation during immunochemotherapy which can delay or prematurely terminate anti-tumor treatment. It is usually considered that patients who are hepatitis B surface antigen-positive (HBsAg+) have a higher rate of HBV reactivation and a poorer prognosis compared with patients who have resolved hepatitis B virus infection (HBsAg+/anti-HBc+).
